A new modality for immunosuppression: targeting the JAK/STAT pathway

JJ O'shea, M Pesu, DC Borie… - Nature reviews Drug …, 2004 - nature.com
JJ O'shea, M Pesu, DC Borie, PS Changelian
Nature reviews Drug discovery, 2004nature.com
Thousands of organs are transplanted each year and millions of people suffer from
autoimmune diseases, which creates a need for an armamentarium of immunosuppressive
drugs. Unfortunately, immunosuppressants have unwanted side effects owing, in part, to the
fact that they have ubiquitous molecular targets. Cytokines have emerged as important
controllers of the immune response, and work during the past decade has identified Janus
kinases (JAKs) and signal transducers, and activators of transcription (STATs), as crucial …
Abstract
Thousands of organs are transplanted each year and millions of people suffer from autoimmune diseases, which creates a need for an armamentarium of immunosuppressive drugs. Unfortunately, immunosuppressants have unwanted side effects owing, in part, to the fact that they have ubiquitous molecular targets. Cytokines have emerged as important controllers of the immune response, and work during the past decade has identified Janus kinases (JAKs) and signal transducers, and activators of transcription (STATs), as crucial intracellular elements in cytokine signalling. Here, we discuss the potential of the JAK/STAT pathway as a target for new immunosuppressants. In particular, the inhibition of JAK3 seems to be an excellent strategy, because of the selective expression and precise functions of this kinase.
nature.com